ArticleMedical oncology (Northwood, London, England)2026
Pachymic acid exhibits synergistic antitumor efficacy with lenvatinib in hepatocellular carcinoma by targeting PPARγ to inhibit glycolysis.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Lenvatinib is a first-line treatment for hepatocellular carcinoma (HCC), though drug resistance may develop with long-term use. to investigate the potential of pachymic acid to enhance lenvatinib's anti-tumor efficacy. HepG2 and LM3 cells were exposed to pachymic acid and/or lenvatinib. Cell proliferation was evaluated using colony formation assays and flow cytometry analysis of apoptosis. Cell invasion was evaluated using wound healing assays and transwell assays. Glucose consumption, lactate production and glycolysis-related protein expression were measured to evaluate aerobic glycolysis status. Tumor-bearing experiments in nude mice were conducted to verify pachymic acid's influence on HCC. Twenty µmol/L pachymic acid substantially inhibited the apoptosis rate (8.5% versus 15.2%, p < 0.001), wound healing rate (59.3% versus 31.0%, p < 0.001), glucose consumption (5.3 µmol/L versus 3.4 µmol/L, p < 0.001) and lactate production (0.7 µmol/L versus 0.3 µmol/L, p < 0.001) in HepG2 cells. Similar results were observed in LM3 cells. Peroxisome proliferator-activated receptor gamma (PPARγ) could be its molecular target that intervenes in aerobic glycolysis of HCC. Notably, pachymic acid exhibited synergistic antitumor efficacy with lenvatinib in both in vitro (cell survival rate: 53.3% in the lenvatinib group versus 33.3% in the pachymic acid + lenvatinib group, p < 0.001) and in vivo models (tumor volume: 483.0 mm
Indexed as
Identifiers
42709355What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.